for educational and safety purposes
Every compound in the sci-wiki that affects anxiety; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
10 sourced · 15 reference
GB-115 is a cleverly designed dipeptide anxiolytic that eases anxiety while keeping the mind clear, a combination almost nothing else in its category manages. Rather than sedating, it blocks the cholecystokinin CCK-1 receptor, a pathway tied specifically to chronic anxiety and panic, and in a clinical study of generalized anxiety disorder it actually sharpened attention and reaction time while it worked. For those seeking calm without the fog, weakness, or dependence of classic sedatives, GB-115 is a genuinely intriguing research anxiolytic.
Carnosic acid is a phenolic diterpene found in the herbs rosemary (Salvia rosmarinus) and common sage (Salvia officinalis), where it is one of the main compounds responsible for their antioxidant activity. Together with its oxidation product carnosol, it is used commercially as a natural antioxidant food preservative, labeled as rosemary extract (E392). It has been studied extensively for antioxidant, anti-inflammatory, and neuroprotective effects, which are largely attributed to its ability to activate the cell's Nrf2 defense pathway.
Etifoxine (brand name Stresam; also called etafenoxine) is a benzoxazine anxiolytic (an anti-anxiety drug from a chemical family unrelated to the benzodiazepines like Valium). It has been prescribed for the anxious, tense, physical side of stress mainly in France and a handful of other countries since the late 1970s, and it is not approved by the US FDA. What makes it interesting is a dual mechanism: it calms the brain both by directly tuning up GABA-A receptors and by nudging the body to make more of its own calming neurosteroids. In head-to-head trials it eased anxiety comparably to some benzodiazepines while causing less sedation, less memory and psychomotor impairment, and little rebound or dependence when stopped. It has also been explored beyond anxiety for helping injured peripheral nerves heal and for damping neuroinflammation (inflammation inside nervous tissue). The important caveat is safety: rare but serious liver injury and severe skin reactions have been reported.
GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the mature mammalian central nervous system, where it lowers the excitability of nerve cells. The same molecule is sold as a dietary supplement marketed for relaxation, stress, and sleep. A long-standing point of debate is that orally taken GABA does not readily cross the blood-brain barrier, so how supplements produce their reported calming effects is not fully settled and may involve the peripheral nervous system and the gut rather than direct action in the brain.
Selank + Semax is a nasal spray pairing two Russian research peptides that are normally sold on their own. Selank is a synthetic relative of the immune peptide tuftsin, studied in Russia as an anxiolytic that does not sedate and does not appear to produce the tolerance or withdrawal that benzodiazepines do. Semax is a shortened fragment of ACTH, cut so that it keeps the behavioural effects without the hormonal ones, and studied for attention, stroke recovery and neuroprotection. Both are reported to raise BDNF, and that shared thread is the usual argument for combining them: one takes the edge off, the other sharpens.
L-THP (levo-tetrahydropalmatine) is a plant alkaloid from Corydalis and related herbs with a long history in traditional Chinese medicine for its calming, sedative, and pain-relieving properties. Modern research has clarified its mechanism as a dopamine receptor modulator, and it has been carried all the way into a human clinical study for cocaine use disorder, an unusually strong evidence base for a botanical compound. For those exploring natural approaches to relaxation, sleep, and discomfort, L-THP is a genuinely well-studied and intriguing choice.
Pregnanolone (3α-hydroxy-5β-pregnan-20-one, also written 3α,5β-tetrahydroprogesterone) is an endogenous neurosteroid, meaning a steroid that acts rapidly on neuronal ion channels rather than through classical intracellular hormone receptors, formed as a reduced metabolite of progesterone. It is the 5β epimer of allopregnanolone and a potent positive allosteric modulator of the GABA-A receptor (the pentameric chloride channel that carries most fast inhibitory signalling in the brain), giving it sedative, anxiolytic, anticonvulsant and anaesthetic properties. Under the International Nonproprietary Name eltanolone it was developed in the 1990s as an intravenous general anaesthetic, formulated in a soybean-oil emulsion after earlier castor-oil-solubilised steroid anaesthetics proved allergenic; smooth induction and cardiovascular stability were offset by slow recovery and skin reactions, and it was never marketed. Its sulfate and synthetic glutamate esters are studied separately as use-dependent inhibitors of the NMDA receptor, an excitatory glutamate channel implicated in excitotoxicity and neuroprotection.
Buspirone is an anxiolytic medication of the azapirone class, used mainly to treat generalized anxiety disorder. It acts chiefly as a partial agonist at the serotonin 5-HT1A receptor and, unlike benzodiazepines, does not cause significant sedation, dependence, or withdrawal. It was approved for medical use in the United States in 1986 and is sold as a generic, formerly under the brand name Buspar.
Tofisopam is an anxiolytic drug of the 2,3-benzodiazepine class, marketed in parts of Europe and Asia under brand names such as Grandaxin [1]. Unlike the familiar 1,4-benzodiazepines such as diazepam, it relieves anxiety without producing sedation, muscle relaxation, memory impairment, or anticonvulsant effects [2]. It is used mainly for anxiety and autonomic symptoms, and it is not approved in the United States or Canada.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder and several anxiety disorders, and available in immediate-release and extended-release forms. It is distinguished by an ascending dose-response relationship: at low doses it behaves much like a selective serotonin reuptake inhibitor, while progressively higher doses recruit norepinephrine reuptake inhibition, which contributes both to added efficacy and to dose-dependent increases in blood pressure. Beyond monoamine transport, preclinical work implicates sigma-1 receptor modulation in its antidepressant action, and the drug is widely repurposed as an effective nonhormonal treatment for menopausal and cancer-therapy-related hot flashes. Network meta-analyses place it among the more efficacious antidepressants, although tolerability, cardiovascular effects in overdose, and a pronounced discontinuation syndrome temper its use.
3α-Androstanediol (5α-androstane-3α,17β-diol) is an endogenous neurosteroid formed as the terminal 3α-reduced metabolite of dihydrotestosterone (DHT, the most potent natural androgen). Despite its androgenic origin it binds the androgen receptor only weakly; its defining pharmacology is potent positive allosteric modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), which produces anxiolytic (anxiety-reducing) and anticonvulsant (seizure-suppressing) effects in animal models. It is widely regarded as the androgenic counterpart of allopregnanolone (the analogous progesterone-derived neurosteroid), and is proposed to mediate much of the influence that testosterone exerts on seizure threshold, anxiety, and mood in males. It additionally acts as a ligand of estrogen receptor beta (ERβ), which may underlie some of its cognitive and neuroprotective actions.
Acaprazine is a phenylpiperazine-class anxiolytic and adrenergic-blocking (adrenolytic) agent that was investigated but never marketed.
Allopregnanolone (chemically 3-alpha-hydroxy-5-alpha-pregnan-20-one, also known as 3-alpha,5-alpha-tetrahydroprogesterone or 3-alpha,5-alpha-THP) is an endogenous neurosteroid synthesized in the brain, adrenal glands and gonads as a downstream metabolite of the hormone progesterone. It is the prototypical inhibitory neuroactive steroid and one of the most potent known positive allosteric modulators (molecules that amplify a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), acting at both synaptic receptors and extrasynaptic delta-subunit-containing receptors. The pharmaceutical formulation of this exact molecule, brexanolone (trade name Zulresso), became in 2019 the first drug ever approved by the United States Food and Drug Administration specifically for postpartum depression, and its orally active analog zuranolone followed in 2023. Beyond its rapid actions on inhibitory neurotransmission, allopregnanolone participates in the stress response, ovarian-cycle and pregnancy physiology, seizure regulation and, as more recently characterized, the suppression of innate-immune inflammatory signaling.
AZD-2327 is an investigational, highly selective delta-opioid receptor agonist that AstraZeneca developed as a potential antidepressant and anxiolytic.
AZD-7268 is an investigational delta-opioid receptor agonist that AstraZeneca developed as a potential oral treatment for major depressive disorder. It reached phase 2 clinical trials before development was discontinued.
D-serine is the D-enantiomer of the amino acid serine and acts as a signaling molecule in the brain, where it serves as a co-agonist at the NMDA subtype of glutamate receptor. It is produced from L-serine by the enzyme serine racemase and is one of the more abundant D-amino acids in mammals, concentrated in regions such as the forebrain. Because NMDA receptors require a co-agonist alongside glutamate in order to open, glia-derived D-serine helps govern synaptic plasticity, learning, and memory; reduced D-serine signaling is central to the NMDA-hypofunction model of schizophrenia, in which serum levels are decreased, and it has also been investigated as an adjunct in major depression and as a predictor of response to ketamine.
Deoxycorticosterone (11-deoxycorticosterone, 21-hydroxyprogesterone; also called cortexone or desoxycortone) is an endogenous steroid hormone made by the adrenal cortex that functions both as a mineralocorticoid and as the metabolic precursor to a potent neurosteroid. Acting through the mineralocorticoid receptor (a ligand-activated transcription factor that governs sodium and water balance), it promotes renal salt retention with an affinity close to that of aldosterone. Its principal relevance to neuropharmacology is as the parent compound of 3-alpha,5-alpha-tetrahydrodeoxycorticosterone (THDOC), a positive allosteric modulator of the GABA-A receptor (the brain's main inhibitory chloride channel) that is released during stress and shapes seizure threshold, anxiety, and hypothalamic-pituitary-adrenal (HPA) axis activity. Deoxycorticosterone should not be confused with the psychedelic amphetamine also abbreviated DOC (2,5-dimethoxy-4-chloroamphetamine), which is an entirely unrelated compound.
Emapunil (developmental codes XBD-173 and AC-5216) is an investigational anxiolytic that acts as a selective, high-affinity agonist of the 18-kDa translocator protein (TSPO), a mitochondrial cholesterol-transport protein once known as the peripheral or mitochondrial benzodiazepine receptor. Rather than binding the central benzodiazepine site itself, emapunil stimulates the brain's own synthesis of neurosteroids, most notably allopregnanolone, which then potentiate GABA-A receptors (the brain's main inhibitory chloride channels) to produce anxiolysis. In a landmark 2009 human panic-provocation study it reduced induced anxiety without the sedation, tolerance, or withdrawal that characterise benzodiazepines. It reached Phase 2 clinical evaluation before development was discontinued, and it remains a widely cited proof of concept for neurosteroid-based anxiolysis.
MIF-1 (Pro-Leu-Gly-NH2), also called melanostatin, is a small endogenous tripeptide made in the body. It was first recognized as the hypothalamic factor that inhibits release of melanocyte-stimulating hormone from the pituitary, and it was later found to act in the brain as a positive allosteric modulator of dopamine D2 receptors. Because of that dopamine-enhancing action it has been studied as a potential treatment for depression and Parkinson's disease.
MTEP is a selective, brain-penetrant negative allosteric modulator (NAM) of metabotropic glutamate receptor subtype 5 (mGluR5). It is one of the standard second-generation research tools, developed after MPEP, for probing the role of mGluR5 in anxiety, fear, addiction, and synaptic plasticity [1][2]. In preclinical models it produces anxiolytic-like effects and modulates negative affect, stress responses, and drug-related behaviors [2][3][4].
Rapastinel (originally GLYX-13) is a tiny four-amino-acid peptide (Thr-Pro-Pro-Thr with an amidated tail) that acts as a functional partial agonist at the glycine site of the NMDA receptor. It was the lead candidate in the wave of rapid-acting antidepressants inspired by ketamine, meant to lift mood within a day without ketamine's dissociation; it looked promising through phase 2 but failed its phase 3 depression trials in 2019.
Tabernanthalog (TBG) is a synthetic analogue of the plant alkaloid ibogaine, engineered to be water-soluble and, according to its developers, non-hallucinogenic and less toxic than the parent compound. It was created in the laboratory of David Olson at the University of California, Davis, as an example of a psychoplastogen, a molecule meant to promote the rewiring of brain circuits. In rodent studies it has shown antidepressant-like effects and has reduced alcohol- and drug-seeking behavior without triggering the responses that signal a psychedelic experience.
THDOC (3-alpha,5-alpha-tetrahydrodeoxycorticosterone) is an endogenous neurosteroid (a steroid that acts rapidly on neuronal membrane receptors rather than on classical nuclear hormone receptors) and the fully reduced 3-alpha,5-alpha metabolite of the adrenal steroid deoxycorticosterone. It is one of the most potent naturally occurring positive allosteric modulators (compounds that amplify a receptor's response to its own transmitter) of the GABA-A receptor, the brain's principal inhibitory chloride ion channel, where it enhances both fast synaptic and sustained extrasynaptic inhibition. Because its synthesis is driven by adrenocorticotropic hormone and by acute stress, THDOC is regarded as a stress-responsive inhibitory neurosteroid that provides negative feedback on the hypothalamic-pituitary-adrenal axis and transiently raises the seizure threshold. Alongside allopregnanolone, it is a prototypical member of the stress-derived GABAergic neurosteroid family.
URB597, also known as KDS-4103, is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme that breaks down the endocannabinoid anandamide. By blocking FAAH, URB597 raises anandamide levels and amplifies endocannabinoid signaling, producing anxiolytic, antidepressant-like, and analgesic effects in animal models without the full intoxicating profile of direct cannabinoid agonists [1][2][3]. It is one of the most extensively used FAAH inhibitor research tools.
Zuranolone (development code SAGE-217; marketed as Zurzuvae) is an orally bioavailable synthetic analog of allopregnanolone (a naturally occurring neurosteroid derived from progesterone) that acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its own transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride channel). It was engineered by Sage Therapeutics from the same neurosteroid scaffold as the intravenous agent brexanolone, but with a modified 3-hydroxy pyrazole substitution that confers metabolic stability suitable for once-daily oral tablets rather than a continuous infusion. In August 2023 the United States Food and Drug Administration approved zuranolone for postpartum depression (a major depressive episode arising in the weeks after childbirth), making it the first oral drug indicated specifically for that condition. It is notable for producing an antidepressant response within days when given as a short, fixed two-week course, in contrast with the weeks-long onset of conventional monoamine antidepressants.